STOCK TITAN
  1. Home
  2. Sec-filings
  3. OKYO
  4. [20-F] OKYO Pharma Limited Files Annual Report (Foreign Issuer)

[20-F] OKYO Pharma Limited Files Annual Report (Foreign Issuer)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
20-F
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock OKYO logo
OKYO PHARMA LTD

NASDAQ:OKYO

OKYO Rankings

#7810 Ranked by Market Cap
N/A Ranked by Dividends

OKYO Latest News

Jul 17, 2025
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
Jul 16, 2025
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
Jun 11, 2025
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
Jun 11, 2025
OKYO Pharma to Present at the Bio International Convention
May 19, 2025
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

OKYO Latest SEC Filings

Jul 17, 2025
[6-K] OKYO Pharma Limited Current Report (Foreign Issuer)
Jul 16, 2025
[6-K] OKYO Pharma Limited Current Report (Foreign Issuer)

OKYO Stock Data

107.03M
25.78M
27.61%
8.94%
1%
Biotechnology
Healthcare
Link
United Kingdom
London